You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Novel A2A Adenosine Agonists in Vascular Protection
SBC: ADENOSINE THERAPEUTICS, LLC Topic: N/ADESCRIPTION (provided by applicant): This is a phase II SBIR proposal to develop a new drug eluting stent to prevent restenosis. It is a 3-way collaboration between Adenosine Therapeutics, LLC, Setagon, Inc., and the University of Virginia. The work described here will be done at Adenosine Therapeutics (compound synthesis and pharmacokinetics) and the University of Virginia (Stent studies in pigs) ...
STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
Incorporating Bone Minerals into Orthopaedic Surfaces
SBC: ADVANCED SURFACES AND PROCESSES, INC. Topic: N/ADESCRIPTION (provided by applicant): Submerged Electro-Spark Deposition (SESD, US patent pending), developed at Advanced Surfaces And Processes, Inc., is a surface modification technique. Any conductive surface can be modified with regards to surface texture and chemical composition. The objective of the present proposal is to use SESD to incorporate appreciable amounts of bone mineral elements, i ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Morpholino Antisense Drugs for Hepatitis C Virus
SBC: Avi Biopharma, Inc. Topic: N/ADESCRIPTION (provided by applicant): Hepatitis C Virus (HCV) causes a persistent infection in most humans exposed to the virus. HCV infection in time can lead to cirrhosis and hepatocellular carcinoma. Although the annual number of newly infected patients has dropped significantly over the past decade, about 4 million people are currently persistently infected in the USA. There is presently no un ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Cord Blood Cells in ALS: Replacement of Protection?
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: N/ADESCRIPTION (provided by applicant): Amyotrophic lateral sclerosis (ALS) is a fatal degenerative disease affecting motor neurons in the spinal cord, brainstem and cortex. We have previously shown that transplanting neuronal cells into the spinal cord delays the onset of motor symptoms in the G93A mouse model of ALS, but developing a potential treatment strategy around a committed neuronal cell or ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Training for Treatment of Adolescent Depression
SBC: DESCHUTES RESEARCH, INC. Topic: N/ADESCRIPTION (provided by applicant): The overall aim of the proposed project is to develop an interactive computer-based program designed to train mental health professionals in use of an established cognitive-behavioral program for the treatment of adolescent depression. The Adolescent Coping With Depression (CWD-A) course has been empirically validated and adapted for a variety of formats (e.g., ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Floor Monitor for Gait Assessment and Falls Detection
SBC: EMPIRICAL TECHNOLOGIES CORPORATION Topic: N/ADESCRIPTION (provided by applicant): Falls among the elderly, one of the most common reasons requiring medical intervention and a contributing factor in 40% of nursing home admissions, are a major health problem. Several studies have identified quantifiable gait markers that appear to distinguish between elderly "fallers" and non-fallers. These studies have relied on data acquired in gait-laborat ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Stimulation of Tear Secretion by a Novel Glycoprotein
SBC: EYERX RESEARCH, INC. Topic: N/ADESCRIPTION (provided by applicant): Dry eye is a ubiquitous, often overlooked, underdiagnosed and poorly understood affliction of the ocular surface. This common opthalmological complaint can markedly affect a patient's quality of life. As a multifactorial disease, dry eye has hyposecretory, auto-immune, inflammatory, hormonal, neurogenic, toxic, and iatrogenic components. Common to all etiologie ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
User adjustable support surfaces for wheelchair comfort
SBC: FALCON REHABILITATION PRODUCTS Topic: N/ADESCRIPTION (provided by applicant): Individuals with disabilities who require the use of wheelchairs for all of their independent mobility often experience problems with chronic seat discomfort in their wheelchairs. In spite of this prevalent problem, very little research has been done and few products have been specifically developed to mitigate chronic wheelchair seat discomfort. Chronic wheel ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Mitochondrial Genomes in Aging & Neurodegeneration
SBC: Gencia Corporation Topic: N/ADESCRIPTION (provided by applicant): Substantial evidence exists to support the hypothesis that oxidatively-damaged mitochondrial genomes contribute to the pathophysiology of aging and neurodegeneration. Damaged mitochondrial genes and mitochondrial oxidative stress contribute to or are primarily causal in bioenergetic failure of tissues, premature cell death of non-mitotic muscle cells and neuron ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Cytochlor/cytofluor: New Tumor Targeted Radiosensitizer
SBC: HALOGENETICS Topic: N/ADESCRIPTION (provided by applicant): Cytochlor Technology is about to enter a Phase I trial as a radiosensitizer of tumors of the oral cavity and oropharynx with NCI supervision. Our objective is to demonstrate Cytochlor's safety, selectivity and possible efficacy (although efficacy is not the goal of a Phase I trial). Our goal is to move Cytochlor Technology to a mutliinstitutional Phase II clini ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health